The Latest
-
Permission granted by EMD Serono
How EMD Serono plans to hit its lofty goals in R&D
The company’s global heads of oncology R&D reveal how strategic partnerships are key to its launch plans following layoffs in the U.S.
-
Permission granted by Organon
Q&A // First 90 DaysOrganon’s chief medical officer wants to change how the world sees women’s health
Dr. Juan Camilo Arjona Ferreira joined Organon in September and says the company is “like a lighthouse in women’s health” in its visibility and focus.
-
iStock via Getty Images
The biopharma COO’s playbook
Connie Chang, COO at ONL Therapeutics, describes what it takes to bring a CEO’s vision to life.
-
Stock via Getty Images
Biohaven wants to muscle in on the Ozempic craze with a competing class of drugs
Biohaven and other companies are aiming to develop meds with a different mechanism of action that trim the waistline while building lean tissue.
-
Stock via Getty Images
A startling drop in U.S. life expectancy — and how pharma could help turn the tide
The recently observed dip was particularly acute for men, who now live an average of 5.8 fewer years than women.
-
Chip Somodevilla via Getty Images
Top FDA official Woodcock to retire early next year
The 37-year veteran helmed the agency’s pandemic response, and was a key decision-maker in controversial calls on opioids, an Alzheimer's therapy and muscular dystrophy drugs.
-
Permission granted by AstraZeneca/U. of Birmingham
Q&AAstraZeneca showed the pandemic isn’t over for immunocompromised patients. What’s next?
Dr. Paul Moss, a hematology expert in the U.K., conducted a study with AstraZeneca showing the alarming extent to which immunocompromised patients are burdened with COVID-19.
-
iStock via Getty Images
The power of genomics-based healthcare remains largely untapped
23andMe co-founder and CEO Anne Wojcicki discusses ways the industry could integrate genomics into healthcare.
-
Permission granted by Talus Bio
Biotech SpotlightA biotech tackles drug discovery with transcription factor know-how
Talus Bio, which developed a platform to map transcription factors, has a lead cancer candidate in the works and consults with other industry players in the complicated biology.
-
Permission granted by Johnson & Johnson Innovative Medicine
6 ways to improve clinical trial diversity — as shown by J&J
Johnson & Johnson Innovative Medicine’s director of diversity, equity and inclusion in clinical trials shares key strategies for making DEI work.
-
Courtesy of Sarepta
Can Sarepta’s Duchenne gene therapy still deliver on its promise?
For Sarepta — and DMD patients — there’s a lot riding on the treatment’s next steps.
-
Stock via Getty Images
Humans can’t shake the mosquito threat. Here’s what pharma has in the pipeline.
The arsenal against the world’s deadliest creature is growing and a universal vaccine is in the works.
-
Stock via Getty Images
5 of the best paid biopharma CEOs
As revenue growth remained high last year, so did biopharma CEO pay in the U.S.
-
Photo illustration: Industry Dive
The 2023 Red Jacket honorees
This year's inductees to the PharmaVoice 100 "hall of fame" are leaders who have been at the forefront — and will stay at the forefront — of industry change.
-
Permission granted by BioMarin
Making MovesDoes BioMarin’s CEO shuffle signal bigger changes ahead?
With its long-time CEO on the way out, the rare disease biotech has seen an activist investor grow its stake.
-
zennie via Getty Images
How pharma leaders talk about ethics in a highly criticized industry
The maze of ethical issues in biopharma can confound even the wiliest executive. How do some leaders get by?
-
Janice Haney Carr/CDC/Sickle Cell Foundation of Georgia/AP
Deep DiveWhat if a CRISPR cure isn’t such an easy choice?
A gene editing therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics can mute sickle cell disease’s most damaging symptoms. Yet treatment may not be as simple as its dramatic benefit makes it seem.
-
Mario Tama / Getty via Getty Images
An at-home flu vaccine? If approved, it could open the door to more DIY options
A new way to administer vaccines at home could help AstraZeneca reach a wider market for FluMist, the nasal influenza vaccine.
-
Permission granted by Avidity
Biotech SpotlightA new delivery method muscling its way into the RNA space
With an AOC platform targeting muscle diseases, Avidity Biosciences hopes to break open the possibilities of RNA.
-
Dia Dipasupil via Getty Images
Q&A23andMe CEO Anne Wojcicki’s vision for changing healthcare as a ‘full-fledged biotech’
23andMe always had bigger aims than at-home genetics testing. In this in-depth interview, the company’s founder explains its foray into pharma, drug R&D, solving cold cases and more.
-
Permission granted by NYU
OpinionThe thorniest questions facing pharma, according to a leading bioethicist
Bioethics guru Arthur Caplan of NYU gives his outspoken and frank opinion on the industry’s minefield of ethical challenges.
-
Mario Tama via Getty Images
The obesity drug effect: What medical device executives are saying
Investor concerns that interest in GLP-1s will slow demand for medical devices and procedures have shaved roughly $370 billion in value from stocks across the medtech sector, according to research by Mizuho.
-
Stock via Getty Images
In a record year for biotech bankruptcy, here are 3 companies that went under
A challenging funding environment and lack of partnering deals have contributed to the market's ongoing troubles.
-
Photo illustration: Industry Dive; Getty Images
PharmaVoice 100PharmaVoice 100s: Entrepreneurs
From biotech startups to a services agency, these entrepreneurs are hedging their bets to offer innovative approaches in patient care.
-
iStock via Getty Images
How Big Pharma keeps the oncology engines hot with a host of strategies
From Merck and J&J to AbbVie and Eisai, the oncology field has stayed consistently devoted to churning out important therapies.
